Spirocyclic compounds, their preparation methods and uses
By developing spirocyclic compounds, the problems of limited variety and poor oxidative stability of existing main protease inhibitors have been solved, resulting in better main protease inhibition and oxidase tolerance, thus improving antiviral activity and drug adherence.
Patent Information
- Application Number
- CN202311857679.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-29
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-12-29
AI Technical Summary
The existing main protease inhibitors are few in number and have poor oxidative stability, which means that they need to be used in combination with ritonavir when taken orally and are not well tolerated, affecting the efficacy and compliance of the drug.
To develop a spirocyclic compound with main protease activity inhibition capacity comparable to or better than nematvir and better oxidase tolerance, and to improve the stability and oxidative metabolism time of the compound through preparation methods, thereby reducing the number of times it can be taken orally per day.
It achieves good antiviral activity and stability in human liver microsomes in vivo, eliminating the need for combination with drugs such as ritonavir, thus improving drug adherence and treatment efficacy.
Smart Images

Figure CN117820325B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a spirocyclic compound, its preparation method, and its uses. Background Technology
[0002] While vaccines have been widely used as a means of boosting herd immunity, SARS-CoV-2 itself is highly prone to mutation, resulting in various circulating mutant strains. When a new mutant strain begins to circulate, those vaccinated against the original strain can still become infected, rendering the vaccine ineffective. Therefore, the development of anti-coronavirus drugs remains a top priority.
[0003] Currently, drugs under development to treat coronaviruses can be divided into several categories based on their different mechanisms of action. Among them, main protease inhibitors, such as main protease inhibitors and RNA polymerase inhibitors, have received widespread attention in the industry due to their respective superior characteristics. The relevant content of main protease inhibitors is described below:
[0004] The main protease (also known as 3CLpro, Mpro, or 3CL protease) is a three-domain cysteine protease encoded by the virus's own genome, playing a crucial role in SARS-CoV-2 replication. The SARS-CoV-2 genome encodes two polyproteins (pp1a and pp1ab) and four structural proteins. These polyproteins are cleaved at 11 different sites by the critical SARS-CoV-2 main protease, producing shorter non-structural proteins essential for viral replication. These non-structural proteins include RdRp, helicases, and the main protease itself, each responsible for different stages of SARS-CoV-2 viral replication. Within the main protease, the predominantly catalytic structure is the Cys145-His41 catalytic binary located in the cleavage between domain I and domain II, and this binary and substrate recognition bag are structurally highly conserved across different subtypes of coronavirus main proteases. Due to the crucial role of the main protease in viral replication and its relatively conserved active structure, it could be a key drug target for anti-coronavirus drugs. Furthermore, no protein similar to the main protease exists in the human body, thus ensuring the safety of drugs that inhibit the main protease. Therefore, developing corresponding main protease inhibitors targeting the main protease shows great promise.
[0005] The main protease typically has Cys145 and four active sites. Existing main protease inhibitors are designed to bind to Cys145 by designing a target and to create corresponding molecular structures based on the characteristics of the four active sites, thereby achieving specific binding to these sites, inhibiting the activity of the main protease, and thus preventing the replication of SARS-CoV-2 in vivo.
[0006] Patent WO2021250648 and Pfizer's published literature disclose a main protease inhibitor: This includes the representative compound PF-07321332 (nematvir). This drug exhibits good anti-SARS-CoV-2 activity and has a certain degree of oral bioavailability and safety, making it suitable for oral administration to treat COVID-19. However, when used orally, it still needs to be combined with ritonavir, and its tolerance to oxidases remains low.
[0007] The exemplary specific compounds disclosed in patent WO2023009187 are shown in the following formula, and such compounds have poor oxidative stability.
[0008] Summary of the Invention
[0009] To overcome the shortcomings of existing technologies, such as the limited variety of compounds that inhibit main proteases and poor oxidase tolerance, this invention provides a spirocyclic compound, its preparation method, and its uses. This type of compound possesses main protease activity inhibition capabilities comparable to or better than nematvir, along with improved oxidase tolerance. It achieves good antiviral activity and stability in human liver microsomes, and is expected to eliminate the need for co-administration with drugs such as ritonavir in clinical use. It also exhibits a longer oxidative metabolism time in vivo, reducing the frequency of daily oral administration and improving medication adherence.
[0010] The present invention provides the following technical solutions to solve the above-mentioned technical problems.
[0011] This invention provides a compound as shown in Formula I or a pharmaceutically acceptable salt thereof.
[0012]
[0013] in,
[0014] X 1 For N or CH; X 2 For -NR X2 CR X3 or CR X4 R X5 ;
[0015] R X2 R X3 R X4 and R X5 Independently -H, -C 1-6 Alkyl groups or -C substituted with one, two, or three halogens. 1-6 alkyl;
[0016] R 3 -H, oxo, halogen, C 1-6 Alkyl groups or -C substituted with one, two, or three halogens. 1-6 alkyl;
[0017] It can be a single bond or a double bond;
[0018] R 1 and R 2 Independently H, -C(O)R 11 -C(O)OR 12 -S(O)2R 13 -C 1-10 Alkyl, -C 3-10 cycloalkyl, -C 6-10 aryl, "a 5-10 membered heteroaryl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms" or "a 3-10 membered heterocyclic alkyl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms"; the -C 1-10 Alkyl group, the -C 3-10 cycloalkyl, the -C 6-10 The aryl group, the "5-10 membered heteroaryl group selected from one, two, or three heteroatoms from N, O, and S, with one, two, or three heteroatoms", and the "3-10 membered heterocyclic alkyl group selected from one, two, or three heteroatoms from N, O, and S, with one, two, or three heteroatoms", are independently optionally surrounded by one, two, or three R groups. a replace;
[0019] R 11 R 12 and R 13 Independently for -C 1-10 Alkyl, -C 3-10 cycloalkyl, -C 6-10 aryl, "a 5-10 membered heteroaryl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms" or "a 3-10 membered heterocyclic alkyl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms", wherein -C 1-10 Alkyl group, the -C 3-10 cycloalkyl, the -C 6-10 The aryl group, the "5-10 membered heteroaryl group selected from one, two, or three heteroatoms from N, O, and S, with one, two, or three heteroatoms", and the "3-10 membered heterocyclic alkyl group selected from one, two, or three heteroatoms from N, O, and S, with one, two, or three heteroatoms", are independently optionally surrounded by one, two, or three R groups.b replace;
[0020] R 4 and R 5 Independent of H, -C 1-10 Alkyl, -C 3-10 cycloalkyl or -C 6-10 aryl; the -C 1-10 Alkyl group, the -C 3-10 cycloalkyl and the -C 6-10 The aryl group can be independently and arbitrarily assigned to one, two, or three R groups. c replace;
[0021] R a Independently cyano, halogen, -C 1-10 Alkyl, -OC 1-10 Alkyl, -C 3-6 cycloalkyl, -OC 3-6 cycloalkyl or -C 6-10 Aryl;
[0022] R b Independently cyano, halogen, -C 1-10 Alkyl, -OC 1-10 Alkyl, -OC 3-6 cycloalkyl or -C 6-10 Aryl;
[0023] R c Independently cyano, halogen, -C 1-10 Alkyl, -OC 1-10 Alkyl, -C 3-6 cycloalkyl, -OC 3-6 cycloalkyl or -C 6-10 Aryl;
[0024] R 6 It is cyano; R 7 It is hydrogen; R 8 It is a halogen; n is 0 or 1;
[0025] When X 1 For CH, X 2 For CR X3 or CR X4 R X5 R 1 and R 2 One group is H, and the other group is -C(O)R 11 -C(O)OR 12 or -S(O)2R 13 R 11 R 12 and R 13 Independently for -C 1-10When alkyl, the -C 1-10 Alkyl groups are represented by one, two, or three R groups. a replace.
[0026] In some embodiments, certain groups in the compound of Formula I or its pharmaceutically acceptable salt have the following definitions, and the definitions of groups not mentioned are as described in any embodiment of the invention (hereinafter referred to as "a preferred embodiment").
[0027] In a certain preferred solution, R X2 and R X3 In the context, the -C 1-6 Alkyl groups can be -C independently. 1-4 Alkyl groups, such as methyl groups.
[0028] In a certain preferred solution, R X2 and R X3 In the context, the -C substituted with one, two, or three halogens 1-6 -C in alkyl groups 1-6 Alkyl groups can be -C independently. 1-4 Alkyl groups, such as methyl groups.
[0029] In a certain preferred solution, R 1 R 2 R 11 R 12 R 13 R 4 R 5 R a R b and R c In the context, the -C 1-10 Alkyl groups and -C groups substituted with one, two, or three halogens. 1-6 -C in alkyl groups 1-6 Alkyl groups can be -C independently. 1-6 Alkyl groups, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as methyl.
[0030] In a certain preferred solution, R 1 R 2 R 11 R 12 and R 13 In the context, the -C 3-10 Cycloalkyl groups can be independently -C 3-6 Cycloalkyl, such as cyclopropyl or cyclobutyl.
[0031] In a certain preferred solution, R a and R c In the context, the -C 3-6 The cycloalkyl group can be cyclopropyl or cyclobutyl independently.
[0032] In a certain preferred solution, R 1 R 2 R 11 R 12 and R 13 In the context, the -C 6-10 The aryl group can be phenyl or naphthyl independently.
[0033] In a certain preferred solution, R 1 and R 2 In this context, "a 5-10 membered heteroaryl group whose heteroatoms are selected from one, two, or three of N, O, and S, and whose number of heteroatoms is one, two, or three" can independently be defined as "a 5-10 membered heteroaryl group whose heteroatoms are selected from N and whose number of heteroatoms is one or two," preferably "a 5-6 membered heteroaryl group whose heteroatoms are selected from N and whose number of heteroatoms is one or two," and more preferably pyridyl (e.g., ...). ) or diazonyl (e.g., 1H-pyrazolyl, and for example, ).
[0034] In a certain preferred solution, R X2 R X3 R X4 R X5 R a R b and R c In this context, the halogen may be F.
[0035] In a preferred embodiment, X 1 It can be N or CH.
[0036] In a preferred embodiment, X 2 For NR X2 or CR X3 .
[0037] In a preferred embodiment, the R X2 -C 1-6 alkyl.
[0038] In a preferred embodiment, the R X3 -C is H or substituted with one, two or three halogens. 1-6 alkyl.
[0039] In a preferred embodiment, the R 3 It is -H or oxidized.
[0040] In a preferred embodiment, the R 1 -C(O)R 11 -C 1-10 Alkyl, -C 3-10 cycloalkyl, -C 6-10Aryl group, "a 5-10 membered heteroaryl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms"; the -C 1-10 Alkyl group, the -C 3-10 cycloalkyl, the -C 6-10 The aryl group and the aforementioned "5-10-membered heteroaryl group, selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms" are independently and optionally surrounded by one, two, or three R groups. a replace.
[0041] Preferably, the R 1 -C(O)R 11 -C 1-4 Alkyl, -C 3-6 Cycloalkyl, phenyl, or "5-6 membered heteroaryl groups with nitrogen as the heteroatom, numbering one or two"; the -C 1-4 Alkyl group, the -C 3-6 The cycloalkyl group, the phenyl group, and the "5-6 membered heteroaryl group with nitrogen as the heteroatom, numbering 1 or 2" are independently and optionally surrounded by 1, 2, or 3 R groups. a replace.
[0042] More preferably, the R 1 -C(O)R 11 The phenyl group or "a 5-6 membered heteroaryl group with nitrogen as the heteroatom, consisting of one or two nitrogen atoms"; the phenyl group and the "5-6 membered heteroaryl group with nitrogen as the heteroatom, consisting of one or two nitrogen atoms" are independently and optionally surrounded by one, two, or three R atoms. a replace.
[0043] In a preferred embodiment, the R 1 Can be
[0044] Preferred More
[0045] In a preferred embodiment, the R 2 For H.
[0046] In a preferred embodiment, the R 11 -C 1-10 Alkyl, -C 3-10 cycloalkyl or -C 6-10 aryl; the -C 1-10 Alkyl group, the -C 3-10 cycloalkyl and the -C 6-10 The aryl group can be independently and arbitrarily assigned to one, two, or three R groups. b replace.
[0047] Preferably, the R 11 -C 1-4 Alkyl, -C 3-6 cycloalkyl or phenyl; the -C 1-4 Alkyl group, the -C 3-6 The cycloalkyl group and the phenyl group may optionally be substituted with one, two or three halogens;
[0048] More preferably, the R 11 -C 3-6 Cycloalkyl.
[0049] In a preferred embodiment, the R 11 It is -CF3, cyclopropyl or phenyl; preferably cyclopropyl.
[0050] In a preferred embodiment, the R 4 -C 1-10 Alkyl; the -C 1-10 Alkyl groups may be optionally surrounded by one, two, or three R's. c replace.
[0051] Preferably, the R 4 -C 1-4 Alkyl; the -C 1-4 Alkyl groups may be optionally surrounded by one or two R groups. c The substitution is that Rc is F, cyclopropyl, cyclobutyl, or methyl; more preferably, the R 4 -C 1-4 Alkyl; the -C 1-4 The alkyl group may optionally be substituted with one cyclopropyl group.
[0052] In a preferred embodiment, the R 4 for Preferred More
[0053] In a preferred embodiment, the R 5 For H.
[0054] In a preferred embodiment, the R a Independently cyano, halogen, -C 1-10 Alkyl or -C 3-6 Cycloalkyl.
[0055] In a preferred embodiment, the R a It can be cyano, halogen, methyl or cyclopropyl independently; preferably cyano, F or methyl.
[0056] In a preferred embodiment, the R b Halogens are independent of each other, with F being preferred.
[0057] In a preferred embodiment, the R c Independent of halogen, -C 1-10 Alkyl or -C 3-6 Cycloalkyl.
[0058] In a preferred embodiment, the R c It can be halogen, methyl, cyclopropyl or cyclobutyl; preferably cyclopropyl.
[0059] In a preferred embodiment, n is 0.
[0060] In a preferred embodiment, the Can be Preferred
[0061] In a preferred embodiment, the Can be Preferred More
[0062] In a preferred embodiment, the compound shown in Formula I may be a compound shown in Formula IA.
[0063]
[0064] Where * represents a chiral carbon atom with S or R configuration;
[0065] Preferably, formula IA is formula IA-1 or formula IA-2:
[0066]
[0067] In a preferred embodiment, the compound shown in Formula I may be a compound shown in Formula I-1, a compound shown in Formula I-2, or a compound shown in Formula I-3, preferably a compound shown in Formula I-2 or a compound shown in Formula I-3; more preferably a compound shown in Formula I-3.
[0068]
[0069] In a preferred embodiment, the compound shown in Formula I-1 may be a compound shown in Formula I-1-A and / or a compound shown in Formula I-1-B.
[0070]
[0071] In a preferred embodiment, the compound shown in Formula I-2 may be a compound shown in Formula I-2-A and / or a compound shown in Formula I-2-B.
[0072]
[0073] In a preferred embodiment, the compound shown in Formula I-3 may be a compound shown in Formula I-3-A and / or a compound shown in Formula I-3-BA.
[0074]
[0075] In a preferred embodiment, each substituent in the compound shown in Formula I is one of Scheme 1, Scheme 2, Scheme 3, Scheme 4, Scheme 5, or Scheme 6:
[0076] Option 1:
[0077] The X 1 Let N be the number of people in the group.
[0078] The X 2 For NR X2 CR X3 or CR X4 R X5 ;
[0079] The R X2 The R X3 The R X4 and the R X5 Independently -H, -C 1-6 Alkyl groups or -C substituted with one, two, or three halogens. 1-6 alkyl;
[0080] The R 3 It is H or oxygen;
[0081] The It can be a single bond or a double bond;
[0082] The R 1 and the R 2 Independently H, -C(O)R 11 -C(O)OR 12 -S(O)2R 13 -C 1-10 Alkyl, -C 3-10 cycloalkyl, -C 6-10 aryl, "a 5-10 membered heteroaryl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms" or "a 3-10 membered heterocyclic alkyl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms", wherein -C 1-10 Alkyl group, the -C 3-10 cycloalkyl, the -C 6-10The aryl group, the "5-10 membered heteroaryl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms", and the "3-10 membered heterocyclic alkyl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms" are independently optionally surrounded by one, two, or three R groups. a replace;
[0083] The R 11 The R 12 and the R 13 Independently for -C 1-10 Alkyl, -C 3-10 cycloalkyl, -C 6-10 aryl, "a 5-10 membered heteroaryl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms" or "a 3-10 membered heterocyclic alkyl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms"; the -C 1-10 Alkyl group, the -C 3-10 cycloalkyl, the -C 6-10 The aryl group, the "5-10 membered heteroaryl group selected from one, two, or three heteroatoms from N, O, and S, with one, two, or three heteroatoms", and the "3-10 membered heterocyclic alkyl group selected from one, two, or three heteroatoms from N, O, and S, with one, two, or three heteroatoms", are independently optionally surrounded by one, two, or three R groups. b replace;
[0084] The R 4 and the R 5 Independent of H, -C 1-10 Alkyl, -C 3-10 cycloalkyl or -C 6-10 aryl; the -C 1-10 Alkyl group, the -C 3-10 cycloalkyl and the -C 6-10 The aryl group can be independently and arbitrarily assigned to one, two, or three R groups. c replace;
[0085] The R a Independently cyano, halogen, -C 1-10 Alkyl, -OC 1-10 Alkyl, -C 3-6 cycloalkyl, -OC 3-6 cycloalkyl or -C 6-10 Aryl;
[0086] The R b Independently cyano, halogen, -C 1-10 Alkyl, -OC 1-10Alkyl, -OC 3-6 cycloalkyl or -C 6-10 Aryl;
[0087] The R c Independently cyano, halogen, -C 1-10 Alkyl, -OC 1-10 Alkyl, -C 3-6 cycloalkyl, -OC 3-6 cycloalkyl or -C 6-10 Aryl;
[0088] The R 6 It is cyano; the R 7 For H; the R 8 It is a halogen; n is 0 or 1;
[0089] Option 2:
[0090] The X 1 For CH;
[0091] The X 2 For NR X2 CR X3 or CR X4 R X5 ;
[0092] The R X2 The R X3 The R X4 and the R X5 Independently -H, -C 1-6 Alkyl group, or -C substituted with one, two, or three halogens. 1-6 alkyl;
[0093] The R 3 It is -H or oxidized;
[0094] The It can be a single bond or a double bond;
[0095] The R 1 and the R 2 Independently H, -C(O)R 11 Or “5-10 membered heteroaryl groups selected from one, two or three of N, O and S, with one, two or three heteroatoms”;
[0096] The R 11 For 1, 2 or 3 R b Replacement -C 1-10 alkyl;
[0097] The R 4 and the R 5 Independent of H, -C1-10 Alkyl, -C 3-10 cycloalkyl or -C 6-10 Aryl; the C 1-10 Alkyl group, the -C 3-10 cycloalkyl and the -C 6-10 The aryl group is optionally surrounded by one, two, or three R groups. c replace;
[0098] The R b Halogens are independent of each other;
[0099] The R c Independently cyano, halogen, -C 1-10 Alkyl, -OC 1-10 Alkyl, -C 3-10 cycloalkyl, -OC 3-6 cycloalkyl or -C 6-10 Aryl;
[0100] The R 6 It is cyano; the R 7 For H; the R 8 It is a halogen; n is 0 or 1;
[0101] Option 3:
[0102] The X 1 Let N be the number of people in the group.
[0103] The X 2 For NR X2 or CR X3 ;
[0104] The R X2 The R X3 The R X4 and the R X5 Independently -H, -C 1-6 Alkyl groups or -C substituted with one, two, or three halogens. 1-6 alkyl;
[0105] The R 3 It is -H or oxidized;
[0106] The It can be a single bond or a double bond;
[0107] The R 1 H, -C(O)R 11 -C 1-10 Alkyl, -C 3-10 cycloalkyl, -C 6-10 The aryl group or "a 5-10 membered heteroaryl group selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms"; the -C1-10 Alkyl group, the -C 3-10 cycloalkyl, the -C 6-10 The aryl group and the aforementioned "5-10-membered heteroaryl group, selected from one, two, or three of N, O, and S, with one, two, or three heteroatoms" are independently and optionally surrounded by one, two, or three R groups. a replace;
[0108] The R 2 For H;
[0109] The R 11 -C 1-10 Alkyl, -C 3-10 cycloalkyl or -C 6-10 Aryl; the -C 1-10 Alkyl group, the -C 3-10 cycloalkyl and the -C 6-10 The aryl group can be independently and arbitrarily assigned to one, two, or three R groups. b replace;
[0110] The R 4 -C 1-10 Alkyl; the -C 1-10 Alkyl groups may be optionally surrounded by one, two, or three R's. c replace;
[0111] The R 5 For H;
[0112] The R a Independently cyano, halogen, -C 1-10 Alkyl or -C 3-6 cycloalkyl;
[0113] The R b Halogens are independent of each other;
[0114] The R c Independently cyano, halogen, -C 1-10 Alkyl or -C 3-6 cycloalkyl;
[0115] The R 6 It is cyano; the R 7 For H; the R 8 It is a halogen; the n is 0;
[0116] Option 4:
[0117] The X 1 For CH, X 2 For CH;
[0118] The R 3 For H;
[0119] The It is a double bond;
[0120] The R 1 -C(O)R 11 Or “5-10 membered heteroaryl groups selected from one, two or three of N, O and S, with one, two or three heteroatoms”;
[0121] The R 2 For H;
[0122] The R 11 For 1, 2 or 3 R b Replacement -C 1-10 alkyl;
[0123] The R 4 -C 1-10 Alkyl; the C 1-10 Alkyl groups are optionally surrounded by one, two, or three R's. c replace;
[0124] The R 5 For H;
[0125] The R b Halogens are independent of each other;
[0126] The R c Halogens are independent of each other;
[0127] The R 6 It is cyano; the R 7 For H; the R 8 It is a halogen; the n is 0;
[0128] Option 5:
[0129] The for
[0130] The R 3 It is -H or oxidized;
[0131] The R 1 -C(O)R 11 -C 1-4 Alkyl, -C 3-6 Cycloalkyl, phenyl, or "5-6 membered heteroaryl groups with nitrogen as the heteroatom, numbering one or two"; the -C 1-4 Alkyl group, the -C 3-6 The cycloalkyl group, the phenyl group, and the "5-6 membered heteroaryl group with nitrogen as the heteroatom, numbering 1 or 2" are independently and optionally surrounded by 1, 2, or 3 R groups. a replace;
[0132] The R 11 It is -CF3, cyclopropyl, or phenyl;
[0133] The R 2 For H;
[0134] The R 4 -C 1-4 Alkyl; the -C 1-4 Alkyl groups may be optionally surrounded by one, two, or three R's. c replace;
[0135] The R 5 For H;
[0136] The R 6 It is cyano; the R 7 For H; the R 8 It is a halogen; n is 0; 1
[0137] Option 6:
[0138] The for
[0139] The R 3 It is -H or oxidized;
[0140] The R 1 -C(O)R 11 The phenyl group or "a 5-6 membered heteroaryl group with nitrogen as the heteroatom, consisting of one or two nitrogen atoms"; the phenyl group and the "5-6 membered heteroaryl group with nitrogen as the heteroatom, consisting of one or two nitrogen atoms" are independently and optionally surrounded by one, two, or three R atoms. a replace;
[0141] The R 11 -C 3-6 cycloalkyl;
[0142] The R 2 For H;
[0143] The R 4 -C 1-4 Alkyl; the -C 1-4 The alkyl group may optionally be substituted with one cyclopropyl group;
[0144] The R 5 For H;
[0145] The R 6 It is cyano; the R 7 For H; the R 8 It is a halogen; n is 0.
[0146] In a preferred embodiment, the compound shown in Formula I is selected from any of the following compounds:
[0147]
[0148]
[0149] In a preferred embodiment, the compound represented by Formula I is selected from any of the following compounds:
[0150]
[0151]
[0152]
[0153] The present invention also provides a method for preparing a compound as shown in Formula I, which includes the following steps: subjecting a compound as shown in Formula II to a dehydration reaction to obtain a compound as shown in Formula I;
[0154]
[0155] Among them, X 1 X 2 R 1 R 2 R 3 R 4 R 5 R 6 R 7 and R 8 As described in any one of the present invention, R 9 for The present invention also provides a compound as shown in Formula II. Among them, X 1 X 2 R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 and R 9 As described in any one of the present invention.
[0156] In a preferred embodiment, the compound represented by Formula II is selected from any of the following compounds:
[0157]
[0158]
[0159] The present invention also provides a compound as shown in Formula III.
[0160] in, for R X2 R X3 R 1 R 2 R 3 R 4 and R 5 As described in any one of the present invention.
[0161] In a preferred embodiment, the compound represented by Formula III is selected from any of the following compounds:
[0162]
[0163] The present invention also provides a pharmaceutical composition comprising the compound shown in Formula I above or a pharmaceutically acceptable salt thereof (e.g., an effective therapeutic amount of the active pharmaceutical ingredient) and a pharmaceutically acceptable carrier.
[0164] The present invention also provides the use of a compound of Formula I, a pharmaceutically acceptable salt thereof, or the above-described pharmaceutical composition in the preparation of a 3CLpro protease inhibitor (e.g., in vivo or in vitro (e.g., a positive control in a laboratory study)).
[0165] The present invention also provides the use of a compound of Formula I, a pharmaceutically acceptable salt thereof, or the above-described pharmaceutical composition in the preparation of a medicament for treating and / or preventing diseases caused by coronavirus infection.
[0166] In a preferred embodiment, the coronavirus is one or more of the following: 229Eα coronavirus, NL63α coronavirus, OC43β coronavirus, HKU1β coronavirus, Middle East Respiratory Syndrome coronavirus (MERS-cov), Severe Acute Respiratory Syndrome coronavirus (SARS-cov), and SARS-cov-2;
[0167] More preferably, the coronavirus is SARS-CoV-2.
[0168] The present invention also provides the use of a compound of Formula I, a pharmaceutically acceptable salt thereof, or the above-described pharmaceutical composition in the preparation of a medicament for the prevention and / or treatment of COVID-19.
[0169] The present invention also provides a method for treating a disease related to coronavirus infection, comprising administering to a subject requiring such treatment a compound of Formula I (preferably, administering to the subject requiring such treatment a therapeutically effective amount of the compound of Formula I), or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof.
[0170] Terminology Definition
[0171] Unless otherwise stated, the terms used in this invention have the following definitions, and the definitions of terms not referred to below are as commonly understood by those skilled in the art.
[0172] The term "pharmaceutically acceptable salt" refers to a salt prepared from a compound with a relatively non-toxic, pharmaceutically acceptable acid or base. When a compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. When the compounds of the present invention contain a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent. When a compound contains both relatively acidic and relatively basic functional groups, it can be converted into a base addition salt or an acid addition salt.
[0173] " at the end of the structural fragment" This means that the structural segment is connected to the rest of the molecule through this site. For example, It refers to cyclopropyl.
[0174] Use wedge keys and dashed keys ( ) represents the absolute configuration of a solid center.
[0175] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0176] The term "oxo" refers to =O or -O. - An oxygen atom replaces two hydrogen atoms or a lone pair of electrons on the same carbon or nitrogen atom, in the form =O or -O. - .
[0177] For example
[0178] The term "alkyl" refers to a saturated, straight-chain or branched monovalent hydrocarbon group having a specified number of carbon atoms. For example, C 1-10 Alkyl groups refer to alkyl groups having 1 to 10 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), such as C. 1-6 Alkyl groups, for example, C 1-4Alkyl groups. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, etc.
[0179] The term "cycloalkyl" refers to a saturated, monocyclic cyclic hydrocarbon group having a specified number of carbon atoms, for example, C10 ... 3-10 Cycloalkyl refers to a cycloalkyl group having 3 to 10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) cyclic carbon atoms, such as C14. 3-6 Cycloalkyl groups. Specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0180] The term "heterocyclic group" refers to a saturated, monocyclic cyclic hydrocarbon substituent having a specified number of ring atoms (e.g., 3-10 members), a specified number of heteroatoms (e.g., 1, 2, 3, 4, or 5), and a specified type of heteroatom (one or more of N, O, and S). Heterocyclic groups are attached to the rest of the molecule via carbon atoms or heteroatoms; they can be attached to the rest of the molecule via a ring with heteroatoms or a ring without heteroatoms. Examples include 3-10 member heterocyclic groups.
[0181] The term "aryl" refers to an aryl group having a specified number of carbon atoms (e.g., C36, C46, C56, C66). 6-10 A cyclic, aromatic monovalent hydrocarbon group, which can be monocyclic or bicyclic (e.g., two). In the case of a bicyclic ring, the monocyclic rings share two atoms and one bond. For example, C 6-10 Aryl groups, including but not limited to oxyphenyl or naphthyl groups.
[0182] The term "heteroaryl" refers to a monocyclic, aromatic, monovalent group having a specified number of ring atoms (e.g., 5-10), a specified number of heteroatoms (e.g., 1, 2, 3, 4, or 5), and a specified type of heteroatom (one or more of N, O, and S). The heteroaryl group is attached to the rest of the molecule via a carbon atom or a heteroatom. Examples include 5-10-membered heteroaryls, and 5-6-membered heteroaryls with nitrogen as the heteroatom, having one or two heteroatoms. Specific examples include, but are not limited to: ).
[0183] Generally, the term "substituted" indicates that one or more hydrogen atoms in a given structure are substituted by a specific substituent. Further, when the group is substituted by more than one of the substituents, the substituents are independent of each other; that is, the more than one substituent can be different or the same. Unless otherwise indicated, a substituent can be substituted at each substituted position of the substituted group. When more than one position in a given structural formula can be substituted by one or more substituents selected from a specific group, the substituents can be substituted at the same or different positions.
[0184] The statement "group B optionally substituted by one or more groups A" means that group B can be unsubstituted or substituted by one or more groups A. For example, the C 1-6 Alkyl groups may be optionally surrounded by one, two, or three R's. 3-2 Replacement refers to C 1-6 The alkyl group can be unsubstituted or surrounded by one, two, or three R groups. 3-2 What it replaced.
[0185] When a listed substituent does not specify which atom it is attached to in a compound included but not specifically mentioned in the general chemical formula, such a substituent may be bonded to any of its atoms. Combinations of substituents and / or their variants are permitted only if such combinations produce stable compounds.
[0186] When a listed group does not explicitly indicate that it has a substituent, the group refers only to the unsubstituted group. For example, when "C 1-6 When "alkyl" is not preceded by the qualifier "unsubstituted or substituted", it refers only to "C". 1-6 "alkyl" itself or "unsubstituted C" 1-6 alkyl".
[0187] Furthermore, it should be noted that, unless otherwise explicitly stated, the descriptive phrase "...independently" used in this invention should be interpreted broadly, meaning that the described entities are independent of each other and can independently be the same or different specific functional groups. More specifically, the descriptive phrase "...independently" can mean either that the specific options expressed by the same symbol in different functional groups do not affect each other, or that the specific options expressed by the same symbol in the same functional group do not affect each other.
[0188] The terms “one or more” or “one or more kinds” refer to 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.
[0189] The term “treatment” refers to a therapeutic approach. When a specific condition is involved, treatment means: (1) alleviating one or more biological manifestations of the disease or condition; (2) interfering with (a) one or more points in a biological cascade that causes or precipitates the condition or (b) one or more biological manifestations of the condition; (3) improving one or more symptoms, effects or side effects associated with the condition, or one or more symptoms, effects or side effects associated with the condition or its treatment; or (4) slowing the development of the condition or one or more biological manifestations of the condition.
[0190] The term "prevention" refers to reducing the risk of developing a disease.
[0191] The term "therapeutic effective amount" refers to the amount of a compound that, when administered to a patient, is sufficient to effectively treat or prevent the disease or condition described herein. The "therapeutic effective amount" will vary depending on the compound, the condition and its severity, and the age of the patient to be treated, but may be adjusted as needed by those skilled in the art. Dosages exceeding this range may also be used depending on the dosage form and the severity of the disease.
[0192] The term "subject" refers to any animal that needs to receive treatment or preventative care for a disease, typically a mammal such as a human. Mammals include, but are not limited to: cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, and humans.
[0193] Without violating common sense in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.
[0194] The reagents and raw materials used in this invention are all commercially available.
[0195] The positive and progressive effects of this invention are as follows: the compounds of this invention have comparable or better main protease activity inhibition ability and better oxidase tolerance, achieving good anti-coronavirus activity and excellent human liver microsomal stability. In clinical use, they do not need to be used in combination with ritonavir, etc., and have a longer oxidative metabolism time in vivo, reducing the number of daily oral doses and helping to improve drug compliance. Detailed Implementation
[0196] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed according to conventional methods and conditions, or as selected according to the product instructions.
[0197] Test conditions:
[0198] Prep-HPLC test parameters:
[0199] Instrument: Agilent;
[0200] Analytical column: Ultimate C18, 5µm, 4.6*150mm;
[0201] Mobile phase: A: 0.05% TFA in H2O, B: 0.05% TFA in ACN;
[0202] Wavelength: 214nm / 254nm;
[0203] Flow rate: 1 ml / min.
[0204] Chiral-HPLC test parameters:
[0205] Chromatographic column: Daicel IH 250*4.6mm, 5μm;
[0206] Mobile phase A: HEX + 0.2% DEA;
[0207] Mobile phase B: IPAMEOH + 0.2% DEA;
[0208] Detection wavelength: 254nm;
[0209] Flow rate: 1 mL / min;
[0210] Injection volume: 10 μL;
[0211] Column temperature: RT;
[0212] Runtime: 14 minutes;
[0213] Isocratic elution program: Mobile phase A: Mobile phase B = 80:20 (V / V).
[0214] Example 1: Synthesis of Intermediates
[0215] Example 1.1 Synthesis of intermediate s1
[0216]
[0217] Step 1:
[0218]
[0219] A 38% aqueous solution of HCHO (45 mL, 623 mmol) was added to a solution of s1-1 (67.0 g, 328 mmol) and NaOH (13.1 g, 328 mmol) in H2O (800 mL). The mixture was stirred at 25 °C for 3 h. Then it was stirred at 110 °C for 3 h. LC-MS showed that the reaction was complete. HCl was added to the reaction mixture at 0 °C to pH = 7 to quench the reaction, and the mixture was then precipitated to give a brown solid. The brown solid was washed with water, filtered, and concentrated under reduced pressure to give s1-2 (51.3 g, 72.2%), a brown solid.
[0220] LCMS: m / z = 217.2 [M+H] + .
[0221] 1H NMR: (400MHz, DMSO-d6) δ = 10.91 (s, 1H), 7.45 (d, J = 8.0Hz, 1H), 7.33 (d, J = 8.0Hz, 1H), 7.08 ( t,J=7.2Hz,1H),7.02-6.96(t,J=7.2Hz,1H),4.28-4.12(m,2H),3.62-3.58(m,2H),3.14(br dd,J=5.1,16.2Hz,2H),2.81(br dd,J=10.3,16.2Hz,1H).
[0222] Step 2:
[0223]
[0224] SOCl2 (98.7 g, 830 mmol) was added to a solution of s1-2 (51.3 g, 237 mmol) in MeOH (1000 mL) at 0 °C. The mixture was stirred at 70 °C for 4 hours. LC-MS showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was diluted with water and quenched with NaHCO3 at 0 °C. It was then extracted with ethyl acetate, the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give s1-3 (43.3 g, 79.3%) as a white solid.
[0225] LCMS: m / z = 231.4 [M+H] + .
[0226] Step 3:
[0227]
[0228] TEA (23.6 g, 233 mmol) and Boc₂O (45.0 g, 206 mmol) were added to a solution of s₁-3 (43.2 g, 188 mmol) in DCM (1000 mL). The mixture was stirred at 25 °C for 16 h. LC-MS showed that the reaction was complete. The reaction mixture was quenched by adding HCl to pH = 6 at 0 °C, then diluted with water and extracted with DCM. The extracted organic layers were combined, washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography (elution of 0–11% ethyl acetate / petroleum ether gradient) to give s₁-4 (60.2 g, 97%) as a white solid.
[0229] LCMS: m / z = 331.1 [M+H] + .
[0230] 1H NMR(400MHz, CHLOROFORM-d)δ=8.42-7.78(m,1H),7.52(d,J=7.6Hz,1H),7.33(dd,J=2.5,7.9Hz,1H),7.20-7.16(m,2H),5.50-5.17( m,1H),4.98-4.77(m,1H),4.66-4.49(m,1H),3.64(d,J=8.2Hz,3H),3.45(d,J=15.5Hz,1H),3.19-3.05(m,1H),1.56(d,J=1.7Hz,9H).
[0231] Step 4:
[0232]
[0233] NBS (16.7 g, 93.8 mmol) and HOAc (407 g, 6.78 mol) were added to a solution of s1-4 (31.0 g, 93.8 mmol) in THF (400 mL) and H2O (400 mL). The mixture was stirred at -5 °C for 1 hour. LC-MS showed that the reaction was complete. The reaction mixture was quenched by adding saturated Na2SO3 solution (200 mL), and then NaHCO3 solution was added to the mixture at 0 °C until pH = 7. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give a white solid s1-5 (32.0 g, 98% yield). The configuration of compound s1-5 was determined with reference to WO2023009187.
[0234] LCMS: m / z = 347.2 [M+H] + .
[0235] 1 H NMR (400MHz, DMSO-d6) δ = 10.67 (s, 1H), 7.27-7.22 (m, 1H), 7.12-6.97 (m, 2H), 6.91 (d, J = 7.8Hz, 1H), 4.67-4 .57(m,1H),3.75-3.68(m,3H),3.59-3.47(m,2H),2.44-2.35(m,1H),2.31-2.19(m,1H),1.41-1.37(m,9H).
[0236] Step 5:
[0237]
[0238] NH4OH (20.6 mL, 144 mmol) was added to a solution of compound s1-5 (500 mg, 1.44 mmol) in MeOH (5 mL) in a sealed tube, and the mixture was stirred at 80 °C for 16 hours. The mixture was concentrated to give compound s1-6 (425 mg, 94% yield) as a white solid.
[0239] LCMS: m / z(ES+) = 354.2[M+Na] + .
[0240] Step 6:
[0241]
[0242] A solution of compound s1-6 (1 g, 3.00 mmol) in HCl / dioxane (10 mL) was stirred at 25 °C for 3 hours. The mixture was concentrated to give compound s1 (1.2 g, crude product) as a white solid.
[0243] LCMS: m / z(ES+) = 232.0[M+H] + .
[0244] 1 H NMR(400MHz, DMSO-d6)δ9.02(brs,1H),8.04(s,1H),7.77(s,1H),7.64(d,J=7.6Hz,1H),7.29–7.27(m,1H), 7.26–7.24(m,1H),7.02–6.98(m,1H),4.61(s,2H),3.46–3.43(m,1H),2.51–2.49(m,2H),2.26–2.25(m,2H).
[0245] Example 1.2 Synthesis of intermediate s2
[0246]
[0247] Step 1:
[0248]
[0249] Burgess reagent (2.04 g, 8.50 mmol) was added to a THF (20 mL) solution of compound s1-6 (564 mg, 1.70 mmol) under N2 conditions, and the mixture was stirred at 25 °C for 3 hours. The mixture was poured into a saturated NaHCO3 solution (20 mL) and extracted with ethyl acetate (10 mL x 3). The organic phase was washed with brine (10 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography to give compound s2-1 (444 mg, 83% yield) as a white solid.
[0250] 1 H NMR (400MHz, CDCl3) δ8.74(s,1H),7.30(d,J=8.0Hz,1H),7.06(t,J=7.6Hz,1H),6.99(d,J=7.6Hz,2H),4.86(dt, J=47.2,7.8Hz,1H),3.89–3.70(m,2H),2.92–2.78(m,1H),2.54(dd,J=13.2,8.3Hz,1H),1.54(d,J=44.0Hz,9H).
[0251] Step 2:
[0252]
[0253] Anisole (124 mg, 1.15 mmol) was added to a solution of compound s2-1 (120 mg, 0.383 mmol) in TFA (2 mL) and ACN (2 mL), and the solution was stirred at 25 °C for 1 hour. The mixture was concentrated, and the residue was quenched with saturated NaHCO3 (20 mL) and then extracted with ethyl acetate (15 mL x 3). The organic phase was washed with brine (15 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography to give compound s2 (64 mg, 78% yield) as a white solid.
[0254] 1 H NMR (400MHz, CDCl3): δ8.23(s,1H),7.26–7.19(m,2H),7.07(td,J=7.6,0.8Hz,1H),6.94(d,J=7.8Hz,1H),4.42(dd, J=8.4,6.5Hz,1H),3.57(d,J=11.2Hz,1H),3.17(d,J=11.2Hz,1H),2.69(dd,J=13.6,6.3Hz,1H),2.56–2.52(m,1H).
[0255] Example 1.3 Synthesis of intermediate 26a
[0256]
[0257] Step 1:
[0258]
[0259] Tf₂O (9.26 g, 32.82 mmol) was added to a solution of 26-1 (4.0 g, 27.36 mmol) and 2,6-dimethylpyridine (5.86 g, 54.73 mmol) in DCM (20 mL) at 0 °C. After addition, the mixture was stirred at 0 °C for 0.5 h. The reaction mixture was extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated under low pressure. The crude product was purified by silica gel chromatography (PE:EtOAc = 1:0–5:1) to give a brown oily compound 26-2 (4.81 g, 63% yield).
[0260] Step 2:
[0261]
[0262] K₂CO₃ (2.59 g, 18.75 mmol) was added to a solution of 26-3 (2.29 g, 9.38 mmol) and 26-2 (3.91 g, 14.06 mmol) in MeCN (10 mL) at 25 °C. The resulting mixture was stirred at 50 °C for 1.5 h under N₂. The reaction mixture was diluted with H₂O (10 mL) and then extracted with ethyl acetate (50 mL * 3). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated under low pressure. The crude product was purified by silica gel chromatography (PE:EtOAc = 10:1 to PE:EtOAc = 5:1) to give compound 26-4 (2.13 g, 5.72 mmol, 61%) as a brown oil.
[0263] MS(ESI+)m / z 373.10[M+H] + .
[0264] Step 3:
[0265]
[0266] LiOH·H₂O (100 mg, 2.38 mmol) was added to a solution of 26-4 (290 mg, 778.70 μmol) in THF (5 mL) and water (1 mL). The mixture was stirred at 25 °C for 3 h. The mixture was then concentrated, diluted with water (10 mL), adjusted to pH 3-4 with 2 mol / L HCl, and extracted with EtOAc (20 mL * 2). The organic layers were combined and concentrated to give a yellow oily 26a.
[0267] MS(ESI+)m / z 359.10[M+H] + .
[0268] Intermediate 27a was synthesized using a method similar to that described above, by adjusting compound 26-3 to... That's all.
[0269]
[0270] LCMS: m / z = 320[M+1] + .
[0271] Example 1.4 Synthesis of intermediate 3a
[0272]
[0273] Step 1:
[0274]
[0275] At 0 °C, compound 3-1 (5.0 g, 38.7 mmol) was mixed with 50 mL of H₂O and 60 mL of an aqueous solution of HBr (48 wt%). A solution of sodium nitrite (4.5 g, 65.22 mmol) in 10 mL of H₂O was added dropwise to the mixture. The mixture was stirred further at 0 °C for 30 min and then heated to 25 °C overnight. The residue was extracted with EtOAc, washed with brine, dried over MgSO₄, and concentrated to give compound 3-2 (7.50 g crude), a yellow oil.
[0276] LC-MS[M+1] + =192.9,194.9.
[0277] Step 2:
[0278]
[0279] SOCl2 (18.49 g, 155.4 mmol, 11.3 mL) was added to a solution of 3-2 (7.5 g, 38.9 mmol) in EtOH (120 mL) at 0 °C, and the mixture was stirred further at 25 °C for 1 h. The solvent was removed from the mixture, and it was purified by rapid silica gel chromatography (PE:EA = 100:1) to give 3-3 (5.5 g, 64.0% yield) as a colorless oil.
[0280] LC-MS[M+1] + =220.9,222.9.
[0281] Step 3:
[0282]
[0283] At 0 °C, NaH (1.13 g, 28.35 mmol) was added to a mixture of 3-4 (2.1 g, 18.90 mmol), 3-3 (5.43 g, 24.57 mmol), and DMF (20 mL), and the mixture was stirred at 0 °C for 1 h. The mixture was quenched with cold water, extracted with EA, and washed with brine. Compound 3-5 was purified by rapid silica gel chromatography (PE:EA = 1:1) to give compound 3-5 as a white solid (3.4 g, 72% yield).
[0284] LC-MS[M+1] + =252.2.
[0285] Step 4:
[0286]
[0287] In an oxygen atmosphere at 25°C, 3-5 (500 mg, 2.0 mmol), cyclopropylboronic acid (854.6 mg, 10.0 mmol), and pyridine-N-oxide (PNO3) were added. A mixture of Cu(OAc)₂ (1.2 g, 5.9 mmol) and pyridine (1.6 g, 19.9 mmol) in DCM (5 mL) was stirred for 12 h. The solvent was removed from the mixture and purified by rapid silica gel chromatography (PE:EA = 70:30) to give compounds 3-6 (100.0 mg, 17% yield) as a white solid.
[0288] LC-MS[M+1] + =292.10.
[0289] Step 5:
[0290]
[0291] LiOH·H2O (13.7 mg, 343.2 μmol) was added to a solution of 3-6 (100 mg, 343.2 μmol) in THF (1 mL) and H2O (1 mL). The mixture was stirred at 25 °C for 1 h. The resulting mixture was extracted with EA, the aqueous layer was acidified with HCl (2 mol / L) to pH 5, extracted with EA, the organic phase was washed with brine, dried over Na2SO4, and concentrated to obtain mixture 3a (80.00 mg, crude product) as a white solid.
[0292] LC-MS[M+1] + =264.2.
[0293] The following compounds were synthesized using a method similar to that described above:
[0294]
[0295]
[0296] Example 1.5 Synthesis of Intermediate 10a
[0297]
[0298] Step 1:
[0299]
[0300] Cyclopropylamine (246.7 mg, 4.3 mmol) and DIEA (1.1 g, 8.6 mmol) were added to a solution of 10⁻¹ (700 mg, 2.9 mmol) in DMSO (3 mL). The mixture was stirred at 130 °C for 1 hour. The crude product was purified by reversed-phase HPLC (ACN / H₂O: 0-100%) to give compound 10⁻² (520 mg, 82%) as a yellow solid.
[0301] LCMS: m / z = 220.2[M+H] + .
[0302] Step 2:
[0303]
[0304] Cs₂CO₃ (1.3 g, 4.1 mmol) and 10⁻³ (368.5 mg, 1.8 mmol) were added to a solution of 10⁻² (300 mg, 1.4 mmol) in dioxane (10 mL). The mixture was stirred at 80 °C for 2 hours. The reaction mixture was extracted with EA, the organic phase was separated, washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give compound 10⁻⁴ (450 mg, crude), a yellow oil.
[0305] LCMS: m / z = 346.0 [M+H] + .
[0306] Step 3:
[0307]
[0308] LiOH·H2O (109.4 mg, 2.6 mmol) was added to a solution of 10⁻⁴ (450 mg, 1.3 mmol) in THF (2 mL) and H₂O (2 mL). The mixture was stirred at 25 °C for 2 hours. The pH of the mixture was adjusted to 4 with HCl (1 mol / L) and then concentrated directly. The product was purified by reversed-phase HPLC (ACN / H₂O: 0-50%) to give compound 10a (224.4 mg, 52%) as a yellow solid.
[0309] LCMS: m / z = 332.2 [M+H] + .
[0310] 1 H NMR (400MHz, CHLOROFORM-d) δ = 7.04 (s, 1H), 6.41 (br s,1H),5.38(dd,J=5.6,9.6Hz,1H),2.92(qt,J=3.7,7.2Hz,1H),2.11-1.97(m,2H),0.92-0.86(m,2H),0.69-0.60(m,3H),0.51(br d,J=7.0Hz,2H),0.14(br dd,J=2.6,13.6Hz,2H).
[0311] The following compounds were synthesized using a method similar to that described above:
[0312] Intermediate 16a:
[0313] Yellow solid
[0314]
[0315] LCMS: m / z = 404.0 [M+H] + .
[0316] 1H NMR(400MHz, DMSO-d6)δ:9.20(s,1H),7.88–7.80(m,2H),7.39(t,J=9.7Hz,1H),7.16(t,J =8.9Hz,1H),5.26(dd,J=5.2,10.2Hz,1H),2.16–2.09(m,1H),2.03–1.96(m,1H),0.60(br s,1H),0.35(ddd,J=4.7,8.4,13.3Hz,2H),0.15–0.08(m,1H),0.00–-0.06(m,1H).
[0317] Example 1.6 Synthesis of intermediate 12a
[0318]
[0319] Step 1:
[0320]
[0321] Add 1.85 mL of aqueous HBr (40%) to 5 mL of an aqueous solution of 12-1 (300 mg, 2.10 mmol), and then add 5 mL of an aqueous solution of NaNO2 (173 mg, 2.51 mmol) to the mixture at 0 °C. Stir the mixture at 25 °C for 16 hours. Extract the reaction mixture with EA (30 mL * 2), separate the organic phase, wash with brine (100 mL), dry with Na2SO4, filter, and concentrate under reduced pressure to obtain a yellow oily substance 12-2.
[0322] 1 H NMR (400MHz, DMSO-d6) δ: 14.62–12.21 (m, 1H), 4.25 (t, J = 7.3Hz, 1H), 2.50–2.32 (m, 1H), 2.03–1.99 (m, 2H), 1.88–1.55 (m, 6H).
[0323] Step 2:
[0324]
[0325] SOCl2 (116 mg, 977 μmol) was added to a 3 mL solution of MeOH (405 mg, 1.90 mmol) of 12-2. The mixture was stirred at 70 °C for 16 hours. The reaction mixture was then concentrated under reduced pressure to obtain a yellow oily substance, 12-3.
[0326] Step 3:
[0327]
[0328] NaHMDS (1 mol / L, 24.7 mL) was added to a THF (80 mL) solution of 1.4 g (10.9 mmol) of 2,4-difluoroaniline at 0 °C under N2. After 1 hour, a THF (10 mL) solution of 12-4 (2.0 g, 8.2 mmol) was added to the mixture. The reaction mixture was then stirred at 0 °C for 2 hours. The reaction mixture was quenched at 0 °C with saturated NH4Cl (50 mL) and then diluted with H2O (50 mL). The two phases were separated, and the aqueous phase was extracted with EA (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the residue. 12-5 (1.6 g, 67%) was obtained by rapid silica gel chromatography as a yellow solid.
[0329] LCMS: m / z = 292.3 [M+H] + .
[0330] Step 4:
[0331]
[0332] Cs₂CO₃ (839 mg, 2.60 mmol) and 12⁻³ (247 mg, 1.12 mmol) were added to a solution of 12⁻⁵ (250 mg, 859 μmol) in dioxane (5 mL). The mixture was stirred at 80 °C for 16 hours. The reaction mixture was extracted with EA (40 mL × 2), the organic phase was separated, washed with brine (30 mL), dried over Na₂SO₄, filtered, concentrated under reduced pressure, and the residue was purified by reversed-phase HPLC to give 12a (115 mg, 32.1%) as a white solid.
[0333] LCMS: m / z = 418.2 [M+H] + .
[0334] 1 H NMR(400MHz, DMSO-d6)δ:13.83–12.83(m,1H),9.22–9.11(m,1H),7.92–7.82(m,1H),7.73(s,1H),7.40-7.36(m,1H),7.20–7.11(m,1H) ,5.17–5.08(m,1H),2.34–2.26(m,1H),2.25–2.15(m,2H),2.02–1.90(m,1H),1.87–1.72(m,3H),1.71–1.63(m,1H),1.58–1.47(m,1H).
[0335] The following compounds were synthesized using a method similar to that described above:
[0336] Intermediate 11a:
[0337] LCMS: m / z = 372.3 [M+H] + .
[0338] 1 H NMR(400MHz,DMSO-d6)δ:9.99(s,1H),7.93(s,1H),7.75(s,1H),7.67(s,1H),7.58(s,1H),5.17–5.13(m,1H),3.75(s,3 H),2.05–1.98(m,1H),1.92–1.89(m,1H),0.50–0.46(m,1H),0.28–0.23(m,2H),0.05–0.02(s,1H),0.00–-0.11(m,1H).
[0339] Example 1.7 Synthesis of Intermediate 15a
[0340]
[0341] Step 1
[0342]
[0343] N,O-bis(trimethylsilylacetamide) was added to a solution of 15-1 (5.00 g, 26.1 mmol) in MeCN (125 mL) at 80 °C. 13.3 g (65.1 mmol) was added to the mixture, which was then stirred at 80 °C for 2 hours. CH3I (5.60 g, 39.1 mmol) was then added to the mixture at 25 °C, and the mixture was stirred at 80 °C for 16 hours. The reaction mixture was extracted with EA. The organic phase was separated, washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the residue, which was then subjected to rapid silica gel chromatography to give a white solid 15-2 (1.30 g, 24.0%).
[0344] LCMS: m / z = 205.9, 207.9 [M+H] + .
[0345] Step 2
[0346]
[0347] The solution of 15-2 (1.10 g, 5.50 mmol) in DMF (20 mL) was purged three times with N2. Then, NaH (329 mg, 8.20 mmol) was added to the mixture at 0 °C and the mixture was stirred for 30 min. Next, the solution of 15-3 (1.70 g, 8.20 mmol) in DMF (10 mL) was added to the reaction mixture. The mixture was stirred at 90 °C for 16 h. The reaction was quenched by adding NH4Cl (100 mL) to the mixture at 25 °C, followed by extraction with EtOAc (100 mL × 2). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography to give 15-4 (1.70 g, 93.0%) as a colorless oil.
[0348] LCMS: m / z = 332.0, 334.0 [M+H] + .
[0349] Step 3
[0350]
[0351] 15-4 (500 mg, 1.50 mmol) was dissolved in cyclopropylamine (6 mL) at 80 °C and stirred for 2 hours. The reaction mixture was cooled to room temperature and then filtered. The filter cake was concentrated under reduced pressure to give 15-5, a white oily substance.
[0352] LCMS: m / z = 309.3 [M+H] + .
[0353] Step 4
[0354]
[0355] Add hydroxy(trimethyl)stanane to a solution of 15-5 (464 mg, 1.50 mmol) in DCE (5 mL). 5.40 g, 30.1 mmol). The mixture was stirred at 80 °C for 16 hours. H2O (2 mL) was added to quench the mixture, followed by filtration and concentration under reduced pressure. The residue was purified by reversed-phase HPLC (ACN:H2O:0-20%) to give a white solid 15a (160 mg, 36.1%).
[0356] LCMS: m / z = 295.2 [M+H] + .
[0357] 1H NMR(400MHz,DMSO-d6)δ:5.09–4.98(m,1H),3.53(s,3H),2.00–1.91(m,1H),1.85–1.75 (m,1H),0.83–0.60(m,2H),0.32–0.22(m,6H),0.06–0.00(m,1H),-0.05–-0.12(m,1H).
[0358] Example 1.8 Synthesis of intermediate 18a
[0359]
[0360] Step 1
[0361]
[0362] To a solution of 15-4 (500 mg, 602 μmol), 1-methylpyrazole-4-amine (190 mg, 1.96 mmol), and dioxane (10 mL), Pd2(dba)3 (137 mg, 151 μmol), Xantphos (87.1 mg, 151 μmol), and Cs2CO3 (1.47 g, 4.52 mmol) were added. The mixture was placed in N2 and stirred at 100 °C under N2 atmosphere for 16 hr. The reaction mixture was extracted with EtOAc (150 mL x 2). The organic phase was separated, washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography to give a yellow solid 18-1 (280 mg, 53.4%).
[0363] LCMS: m / z = 349.2 [M+H] + .
[0364] Step 2
[0365]
[0366] To a mixture of 18-1 (267 mg, 766 μmol) in THF (2 mL), H₂O (2 mL), and MeOH (2 mL), NaOH (184 mg, 4.60 mmol) was added. The mixture was stirred at 0 °C for 2 hours. The pH of the reaction solution was adjusted to 4 with HCl (1 mol / L), and the mixture was extracted with EtOAc (20 mL × 3). The organic phase was separated, washed with 30 mL of brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase HPLC (H₂O) to give 18a (30 mg, 11.7%) as a white solid.
[0367] LCMS: m / z = 335.3 [M+H]+ .
[0368] 1 H NMR (400MHz, DMSO-d6) δ: 9.10 (s, 1H), 7.93 (s, 1H), 7.58 (s, 1H), 4.99 (dd, J = 4.9, 10.3Hz, 1H), 3.81 (s,3H),3.47(s,3H),2.08–1.93(m,2H),0.59–0.49(m,1H),0.30–0.22(m,2H),0.00–-0.20(m,2H).
[0369] The following compounds were synthesized using a method similar to that described above:
[0370]
[0371] Example 1.9 Synthesis of intermediate 22a
[0372]
[0373] Step 1:
[0374]
[0375] Compound 22-1 (3 g, 15.9 mmol), 4-amino-3-fluorobenzonitrile (2.59 g, 19.1 mmol), Pd2(dba)3 (1.45 g, 1.59 mmol), Xantphos (918 mg, 1.59 mmol), Cs2CO3 (15.5 g, 47.6 mmol), and dioxane (30 mL) were mixed, degassed, and purged three times with N2. The mixture was then stirred at 80 °C under N2 atmosphere for 3 hours. The reaction mixture was diluted with EA (30 mL) and H2O (40 mL), the yellow solid was separated and filtered, and the filter cake was concentrated under vacuum to give compound 22-2 (2.9 g, crude) as a yellow solid.
[0376] LCMS: m / z = 245.1 [M+H] + .
[0377] Step 2:
[0378]
[0379] TMSCl (1.07 g, 9.83 mmol) and NaI (1.47 g, 9.83 mmol) were added to a solution of 22-2 (1.2 g, 4.91 mmol) in 10 mL of ACN. The mixture was stirred at 50 °C for 2 hours. The reaction mixture was filtered to obtain a residue, which was a brown solid, 22-3 (1.3 g, crude).
[0380] LCMS: m / z = 231.0 [M+H] + .
[0381] Step 3:
[0382]
[0383] Add 22-4 (576 mg, 2.39 mmol), NaI (325 mg, 2.17 mmol), and Cs₂CO₃ (1.42 g, 4.34 mmol) to a solution of 22-3 (500 mg, 2.17 mmol) in DMF (20 mL). Stir the mixture at 80 °C for 3 hours. Extract the reaction mixture with EA (150 mL x 2). Wash the organic phase with brine (150 mL), dry to Na₂SO₄, filter, and concentrate under reduced pressure. The residue was purified by rapid silica gel chromatography to give a white solid 22-5 (290 mg, 34.2%).
[0384] LCMS: m / z = 391.2 [M+H] + .
[0385] Step 4:
[0386]
[0387] LiOH·H2O (58.1 mg, 1.38 mmol) was added to a solution of 22-5 (270 mg, 691 μmol) in THF (10 mL) and H2O (2 mL). The mixture was stirred at 25 °C for 20 min. The mixture was extracted with EA. The aqueous layer was separated, and the pH of the aqueous layer was adjusted to 5–6 with 1 mol / L HCl, and then extracted again with EA. The organic layers were combined, washed with brine (60 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a yellow solid 22a (230 mg, crude product).
[0388] LCMS: m / z = 363.2 [M+H] + .
[0389] The following compounds were synthesized using a method similar to that described above:
[0390]
[0391] Example 2: Synthesis of the compound
[0392] Synthesis of compound 26:
[0393]
[0394] Step 1:
[0395] At 0 °C, s1 (200.00 mg, 579.25 μmol, TFA), HATU (413.78 mg, 1.09 mmol), and NMM (256.84 mg, 2.54 mmol) were added to 26a in DMF (4 mL). The mixture was stirred at 0 °C for 2 h, quenched with NH4Cl (10 mL, aq, sat.), extracted with ethyl acetate (10 mL * 2), and purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10 / 1 to 0 / 1) to obtain 26a-1.
[0396] MS(ESI+)m / z = 594.10 [M+Na] + .
[0397] Step 2:
[0398] Add 5% Pd / C (100 mg, 227.42 μmol, 5% purity) to an 8 mL THF solution of 26a-1 (130 mg, 227.42 μmol). Degas the mixture three times, then stir it for 1 h at 25 °C under a H2 atmosphere. Filter and concentrate the mixture to give 26a-2 (100.00 mg, crude) as a yellow solid, which requires no further purification for the next step.
[0399] MS(ESI+)m / z = 460.20[M+Na] + .
[0400] Step 3:
[0401] TFAA (216.04 mg, 1.03 mmol, 142.98 μL) and TEA (208.17 mg, 2.06 mmol, 286.73 μL) were added to a solution of 26a-2 (90 mg, 205.72 μmol) in DCM (5 mL). The mixture was stirred at 30 °C for 3 h. The mixture was washed with water (5 mL x 3). The organic layer was concentrated and purified by prep-HPLC to give compound 26 (9.2 mg) as a white solid.
[0402] MS(ESI+)m / z = 538.10 [M+Na] + .
[0403] 1H NMR(400MHz, DMSO-d6)δ10.72(d,J=9.9Hz,1H),10.39(s,0.4H),10.06(s,0.6H),7.97-7.93(m,1H),7.74-7.63(m 1H),7.29-7.01(m,2H),6.91-6.78(m,2H),6.52-6.44(m,1H),5.78-5.73(m,1H),5.20-5.12(m,1H),4.08-3 .62(m,2H),2.68-2.59(m,1H),2.47-2.43(m,1H),2.09-1.77(m,2H),1.39-1.28(m,1H),0.96-0.69(m,6H).
[0404] Synthesis of compound 11:
[0405]
[0406] Step 1:
[0407]
[0408] NMM (65.3 mg, 646.3 μmol) and HATU (122.8 mg, 323.1 μmol) were added to a solution of 11a (60 mg, 161.5 μmol) and s1 (37.3 mg, 161.5 μmol) in DMF (2 mL). The reaction mixture was stirred at 25 °C for 1 h. The reaction was then quenched with water (10 mL) and extracted with EtOAc (10 mL × 3). The organic phases were combined, washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by rapid silica gel chromatography (DCM:MeOH = 10:1) to give a white solid 11a-1 (80.0 mg, 80%).
[0409] LC-MS[M+1] + =585.3.
[0410] Step 2:
[0411]
[0412] Burr's reagent (306.6 mg, 1.2 mmol) was added to a solution of 11a-1 (75.0 mg, 128.3 μmol) in DCM (5 mL), and the mixture was stirred at 25 °C for 2 h. The solvent was removed under reduced pressure and the residue was purified by prep-HPLC to give 11-P1 (11 mg, 15%) and 11-P2 (13 mg, 18%) as white solids.
[0413] Among them, one is compound 11-P1 and the other is compound 11-P2.
[0414] 11-P1
[0415] LC-MS: m / z = 567.0 [M+1] + .
[0416] 1H NMR(400MHz,DMSO-d6)δ:10.69(s,1H),9.97(s,1H),7.98(s,1H),7.71(s,1H),7.51(s,1H), 7.13(td,J=7.6,1.2Hz,1H),6.93(d,J=7.2Hz,1H),6.86–6.80(m,2H),5.72(d,J=8.0Hz,1H), 5.23–5.19(m,1H),4.12–4.09(m,2H),3.82(s,3H),2.67–2.60(m,1H),2.52–2.47(m,1H),2. 07–1.86(m,2H),0.70–0.62(m,1H),0.44–0.31(m,2H),0.22–0.16(m,1H),0.10–0.04(m,1H).
[0417] 11-P2
[0418] LC-MS: m / z = 567.0 [M+1] + .
[0419] 1H NMR(400MHz, DMSO-d6)δ:10.71(s,1H),10.15(s,1H),8.02(s,1H),7.75(s,1H),7.44(s,1H),7.26(td,J=7.6,8.0 Hz,1H),7.19(d,J=7.2Hz,1H),7.00(td,J=7.2,1.2Hz,1H),6.90(d,J=8.0Hz,1H),5.57(d,J=8.0Hz,1H),5.23–5. 19(m,1H),4.03(d,J=10.4Hz,1H),3.94(d,J=10.4Hz,1H),3.83(s,3H),2.68–2.62(m,1H),2.52–2.44(m,1H),2.0 4–1.97(m,1H),1.89–1.80(m,1H),0.66–0.60(m,1H),0.36–0.30(m,1H),0.21–0.08(m,2H),0.008–0.005(m,1H).
[0420] The following compounds were synthesized using a method similar to that described above:
[0421] Compound 12: synthesized from compound 12a.
[0422] LC-MS: m / z = 613.5 [M+1] + .
[0423] 1 H NMR(400MHz,DMSO-d6)δ:10.72–10.71(m,1H),9.24(s,0.5H),9.05(s,0.5H),7. 88–7.73(m,1H),7.64(s,0.6H),7.58(s,0.4H),7.41–7.34(m,1H),7.20–7.05(m, 2.8H),6.94–6.80(m,2.2H),5.57–5.47(m,1H),5.23–5.18(m,1H),4.08–3.89(m, 2H),2.69–2.59(m,1H),2.48–2.44(m,1H),2.22–2.08(m,3H),2.04–1.49(m,6H).
[0424] Chiral HPLC: The ratio of a pair of isomers is ~1:1.
[0425] These are two stereoisomers of compound 12.
[0426] Compound 13: Synthesized from compound 13a.
[0427] Compound 13 was purified by Prep-HPLC to obtain the following two isomers.
[0428] Among them, one is compound 13-P1 and the other is compound 13-P2.
[0429] 13--P1
[0430] LC-MS: m / z = 530.4 [M+1] + .
[0431] 1H NMR(400MHz,DMSO-d6)δ:10.65(s,1H),9.27(s,1H),7.86(s,1H),7.53(s,1H),7.24 –7.07(m,1H),6.93–6.81(m,3H),5.89–5.45(m,1H),5.05–4.98(m,1H),3.79(s,4H), 3.73–3.68(m,1H),3.40(s,3H),2.67–2.60(m,1H),2.46–2.33(m,1H),2.11–1.82(m ,2H),0.66–0.56(m,1H),0.38–0.22(m,2H),0.09–0.03(m,1H),-0.12–-0.15(m,1H).
[0432] 13-P2
[0433] LC-MS: m / z = 530.4 [M+1] + .
[0434] 1 H NMR(400MHz, DMSO-d6)δ:10.71(s,1H),9.37(s,1H),7.94(s,1H),7.57(s,1H),7.26(td,J=7.6,1. 2Hz,1H),7.03–6.96(m,2H),6.90(d,J=7.6Hz,1H),5.37–5.31(m,1H),5.23–5.19(m,1H),3.81–3.7 8(m,3H),3.50(s,3H),3.41–3.36(m,2H),2.40–2.32(m,1H),2.24–2.16(m,1H),2.02–1.95(m,1H), 1.63–1.56(m,1H),0.66–0.60(m,1H),0.34–0.20(m,2H),0.06–0.016(m,1H),-0.20–-0.25(m,1H).
[0435] Compound 14: synthesized from compound 14a.
[0436] Compound 14 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0437] Among them, one is compound 14-P1 and the other is compound 14-P2.
[0438] 14-P1
[0439] LC-MS: m / z = 562.3 [M+1] +.
[0440] 1 H NMR(400MHz,DMSO-d6)δ:10.73(s,1H),8.29(s,1H),7.83–7.70(m,1H),7.37–7.24(m,2 H),7.11–6.90(m,4H),5.37–5.31(m,1H),5.25(t,J=8.4Hz,1H),3.55(d,J=10.4Hz,1H) ,3.41–3.36(m,4H),2.57–2.54(m,1H),2.43–2.37(m,1H),2.27–2.20(m,1H),1.62–1.5 4(m,1H),0.68–0.59(m,1H),0.36–0.20(m,2H),0.06–0.02(m,1H),-0.15–-0.22(m,1H).
[0441] 14-P2
[0442] LC-MS: m / z = 562.3 [M+1] + .
[0443] 1 H NMR(400MHz,DMSO-d6)δ:10.68(s,1H),8.27(s,1H),7.77–7.65(m,1H),7.36–7.31(m,1H),7 .26–7.06(m,2H),6.94–6.84(m,3H),5.51-5.47(m,1H),5.05(t,J=8.0Hz,1H),3.70(d,J=10 .8Hz,1H),3.57(d,J=10.4Hz,1H),3.30(s,3H),2.61–2.53(m,1H),2.46–2.41(m,1H),2.11– 1.85(m,2H),0.70–0.64(m,1H),0.35–0.30(m,2H),0.13–0.06(m,1H),-0.07–-0.13(m,1H).
[0444] Compound 15: Synthesized from compound 15a.
[0445] Compound 15 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0446] Among them, one is compound 15-P1 and the other is compound 15-P2.
[0447] 15-P1:
[0448] LC-MS: m / z = 490.30 [M+H] + .
[0449] 1 H NMR(400MHz,CD3OD)δ:7.28–7.21(m,1H),7.07–6.90(m,3H),5.57–5.53(m,1 H),5.44–5.32(m,1H),3.51–3.45(m,2H),3.39(s,3H),2.62(d,J=8.0Hz,1H), 2.48–2.32(m,1H),2.31–2.23(m,1H),2.06–2.00(m,1H),1.78–1.58(m,1H),0 .75–0.62(m,3H),0.59–0.25(m,4H),0.11–0.03(m,1H),-0.08–-0.18(m,1H).
[0450] 15-P2:
[0451] LC-MS: m / z = 490.30 [M+H] + .
[0452] 1 H NMR(400MHz,CD3OD)δ:7.30–7.23(m,1H),7.07–6.94(m,3H),5.43–5.32( m,1H),5.25–5.19(m,1H),3.66–3.60(m,1H),3.51–3.45(m,4H),2.63–2. 52(m,2H),2.38–2.00(m,2H),1.65–1.57(m,1H),0.91–0.88(m,1H),0.75 –0.51(m,4H),0.41–0.26(m,2H),0.15–0.03(m,1H),-0.13–-0.18(m,1H).
[0453] Compound 17: Synthesized from compound 17a.
[0454] Compound 17 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0455] Among them, one is compound 17-P1 and the other is compound 17-P2.
[0456] 17-P1
[0457] LC-MS: m / z = 580.0 [M+1] + .
[0458] 1 H NMR(400MHz,DMSO-d6)δ:10.69(s,1H),8.56(s,1H),7.31–7.17(m,3H),7.00–6.8 6(m,3H),5.56–5.48(m,1H),5.10–5.04(m,1H),3.71(d,J=10.4Hz,1H),3.58(d,J =10.8Hz,1H),3.21(s,3H),2.67–2.57(m,1H),2.47–2.41(m,1H),2.12–1.88(m,2 H),0.68–0.54(m,1H),0.40–0.24(m,2H),0.12-0.06(m,1H),-0.10–-0.19(m,1H).
[0459] 17-P2
[0460] LC-MS: m / z = 580.0 [M+1] + .
[0461] 1 H NMR (400MHz, DMSO-D6) δ10.74(s,1H),8.63(s,1H),7.31–7.24(m,3H),7.04–6.97(m,2H),6. 91(d,J=8.0Hz,1H),5.40–5.36(m,1H),5.23(t,J=8.8Hz,1H),3.51(d,J=10.4Hz,1H),3.41( d,J=10Hz,1H),3.26(s,3H),2.59–2.52(m,1H),2.43–2.38(m,1H),2.28–2.22(m,1H),1.63– 1.55(m,1H),0.63–0.59(m,1H),0.34–0.21(m,2H),0.07–0.01(m,1H),-0.20–-0.27(m,1H).
[0462] Compound 18: Synthesized from compound 18a.
[0463] Compound 18 was purified by Prep-HPLC to obtain the following two isomers.
[0464] Among them, one is compound 18-P1 and the other is compound 18-P2.
[0465] 18-P1:
[0466] LC-MS: m / z = 530.30 [M+H] + .
[0467] 1H NMR(400MHz,DMSO-d6)δ:10.66(s,1H),8.72(s,1H),7.59(s,1H),7.25–7.13(m,1H),7.00–6.80 (m,3H),6.39(s,1H),5.49–5.36(m,1H),5.09–4.99(m,1H),3.74(s,3H),3.68(d,J=11.2Hz,1H), 3.56(d,J=11.2Hz,1H),3.35(s,3H),2.60–2.54(m,1H),2.47–2.40(m,1H),2.20–2.03(m,1H),1 .91–1.81(m,1H),0.68–0.57(m,1H),0.39–0.23(m,2H),0.11–0.03(m,1H),-0.10–-0.18(m,1H).
[0468] 18-P2:
[0469] LC-MS: m / z = 530.30 [M+H] + .
[0470] 1H NMR (400MHz, DMSO-d6) δ: 10.72 (s, 1H), 8.70 (s, 1H), 7.60 (d, J = 2.4Hz, 1H), 7.26 (d, J = 7.2Hz, 1H), 7. 03–6.89(m,3H),6.46(d,J=2.4,1H),5.36–5.32(m,1H),5.23–5.19(m,1H),3.74(s,3H),3.49(d,J=10 .4Hz,1H),3.44(s,3H),3.38(d,J=10.4Hz,1H),2.57–2.52(m,1H),2.43–2.32(m,1H),2.25–2.18(m,1 H),1.62–1.54(m,1H),0.66–0.58(m,1H),0.34–0.22(m,2H),0.06–0.01(m,1H),-0.18–-0.24(m,1H).
[0471] Compound 19: Synthesized from compound 19a.
[0472] Compound 19 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0473] Among them, one is compound 19-P1 and the other is compound 19-P2.
[0474] 19-P1:
[0475] LC-MS: m / z = 580.4 [M+H] + .
[0476] 1 H NMR(400MHz, CD3OD)δ:8.15–7.94(m,1H),7.32–7.13(m,2H),7.09–6.87(m,3H),5.94–5.87(m,0. 2H),5.63–5.59(m,0.8H),5.19–5.03(m,1H),3.83(d,J=10.8Hz,1H),3.68–3.57(m,1.6H),3.46(s ,2.4H),2.89–2.77(m,0.2H),2.63(d,J=8.4Hz,1.8H),2.33–2.26(m,1H),1.86–1.77(m,0.8H),1 .75–1.66(m,0.2H),0.78–0.68(m,1H),0.46–0.33(m,2H),0.14–0.08(m,1H),0.00–-0.07(m,1H).
[0477] 19-P2:
[0478] LC-MS: m / z = 580.4 [M+H] + .
[0479] 1 H NMR(400MHz,CD3OD)δ:8.15–8.08(m,1H),7.31–7.24(m,2H),7.08–6.97(m ,2H),6.94(d,J=8.0Hz,1H),5.49–5.46(m,1H),5.24(t,J=8.8Hz,1H),3.62 –3.52(m,5H),2.65–2.53(m,2H),2.42–2.36(m,1H),1.69–1.57(m,1H),0.7 7–0.67(m,1H),0.44–0.26(m,2H),0.11–0.01(m,1H),-0.09–-0.16(m,1H).
[0480] Compound 20: synthesized from compound 20a.
[0481] Compound 20 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0482] Among them, one is compound 20-P1 and the other is compound 20-P2.
[0483] 20-P1:
[0484] LC-MS: m / z = 518.2 [M+H] + .
[0485] 1 H NMR(400MHz,CD3OD)δ:7.24–7.20(m,1H),7.04–6.94(m,2H),6.90(d,J=8.0Hz,1H),5.58 –5.53(m,1H),5.06–5.01(m,1H),3.80(d,J=10.8Hz,1H),3.60(d,J=10.4Hz,1H),3.46(s, 3H),2.69–2.56(m,2H),2.31–2.24(m,1H),2.00–1.87(m,1H),1.83–1.60(m,1H),0.98–0. 86(m,4H),0.76–0.67(m,1H),0.44–0.32(m,2H),0.12–0.06(m,1H),-0.03–-0.09(m,1H).
[0486] 20-P2:
[0487] LC-MS: m / z = 518.3 [M+H] + .
[0488] 1 H NMR(400MHz,CD3OD)δ:7.28(td,J=7.6,0.8Hz,1H),7.07–6.94(m,3H),5.44– 5.40(m,1H),5.23(t,J=8.8Hz,1H),3.61–3.47(m,5H),2.64–2.53(m,2H),2. 40–2.33(m,1H),1.96–1.89(m,1H),1.66–1.58(m,1H),0.99–0.87(m,4H),0. 76–0.66(m,1H),0.43–0.29(m,2H),0.09–0.03(m,1H),-0.07–-0.15(m,1H).
[0489] Compound 16: Synthesized from compound 16a.
[0490] LC-MS: m / z = 599.3 [M+H] + .
[0491] 1H NMR(400MHz,DMSO-d6)δ:10.72(s,1H),9.27(s,0.5H),9.08(s,0.5H),7.81–7.74(m, 1H),7.67–7.59(m,1H),7.41–7.34(m,1H),7.28–7.12(m,3H),6.92–6.84(m,2H),5.7 2–5.59(m,1H),5.24–5.20(m,1H),4.11–3.97(m,2H),2.69–2.52(m,2H),2.11–1.82( m,2H),0.73–0.60(m,1H),0.48–0.31(m,1H),0.21–0.10(m,2H),-0.02–-0.04(m,1H).
[0492] Chiral HPLC: The ratio of a pair of isomers is ~55:45.
[0493] These are two stereoisomers of compound 16.
[0494] Compound 22: synthesized from compound 22a.
[0495] Compound 22 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0496] Among them, one is compound 22-P1 and the other is compound 22-P2.
[0497] LCMS::m / z = 558.1 [M+H] + .
[0498] 22-P1:
[0499] 1H NMR(400MHz,DMSO-d6)δ=10.73(br s,1H),8.58–8.46(m,2H),7.92(dd,J=1.8,11.3Hz,1H),7.73(dd,J=1.1,8.5Hz,1H),7.30(d, J=4.9Hz,1H),7.11(d,J=4.8Hz,1H),7.00–6.94(m,1H),6.81(d,J=7.8Hz,1H),6.73–6.60(m,2 H),5.87(dd,J=5.9,7.4Hz,1H),5.20(t,J=7.9Hz,1H),4.09(d,J=10.8Hz,1H),3.95(d,J=10.6 Hz,1H),2.65–2.58(m,1H),2.50–2.37(m,3H),1.36(d,J=18.1Hz,3H),1.31(d,J=18.0Hz,3H).
[0500] 22-P2:
[0501] 1 H NMR (400MHz, DMSO-d6) δ=10.77–10.53(m,1H),8.90–8.74(m,1H),8.60(t,J=8.4Hz,1H),7.93(dd,J =1.8,11.2Hz,1H),7.78–7.69(m,1H),7.33–7.19(m,3H),7.12(d,J=4.8Hz,1H),7.03(t,J=7.7Hz,1 H),6.91(d,J=7.7Hz,1H),5.82(dd,J=5.0,7.8Hz,1H),5.20(dd,J=6.4,8.8Hz,1H),3.94(d,J=10.6 Hz,1H),3.79(d,J=10.3Hz,1H),2.65(dd,J=8.8,13.4Hz,1H),2.49–2.34(m,3H),1.35–1.21(m,6H).
[0502] Compound 3: Synthesized from compound 3a.
[0503] Compound 3 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0504] Among them, one is compound 3-P1 and the other is compound 3-P2.
[0505] 3-P1
[0506] LC-MS: m / z = 459.3 [M+1] +.
[0507] 1 H NMR(400MHz, DMSO-d6)δ10.73(s,1H),7.22–7.17(m,1H),6.87–6.79(m,5H),5.59(t,J=7.6Hz,1H),5.14-5.11(m,1H),4.01–3.66(m,2H),2.65–2 .60(m,2H),2.03–1.94(m,1H),1.88-1.81(m,2H),0.66–0.59(m,3H),0.5 2–0.44(m,2H),0.39–0.32(m,2H),0.19–0.10(m,1H),0.07–0.04(m,1H).
[0508] 3-P2
[0509] LC-MS: m / z = 459.30 [M+1] + .
[0510] 1 H NMR(400MHz,DMSO-d6)δ10.70(s,1H),7.28-7.24(m,1H),7.17-7.15(m,1H),7.03– 6.97(m,1H),6.93–6.84(m,3H),5.50(t,J=7.5Hz,1H),5.23-5.19(m,1H),4.01–3. 82(m,2H),2.75–2.63(m,2H),2.06–1.87(m,2H),1.82–1.70(m,1H),0.81–0.61(m, 5H),0.35–0.29(m,1H),0.24–0.20(m,1H),0.12–0.08(m,1H),-0.02–-0.07(m,1H).
[0511] Compound 4: Synthesized from compound 4a
[0512] LCMS: m / z = 513.0 [M+1] + .
[0513] 1H NMR (400MHz, DMSO-d6) δ10.72(s,1H),8.66(d,J=2.0Hz,0.5H),8.40(d,J=2.2Hz,0.5H),8.25-8.19(m,1H),7 .20-7.00(m,7H),6.99(d,J=1.9Hz,2H),5.68-5.58(m,1H),5.25-5.16(m,1H),4.16(d,J=10.7Hz,0.5H),4.02 (dd,J=20.0,10.6Hz,1H),3.82(d,J=10.6Hz,0.5H),2.67-2.61(m,1H),2.03-1.96(m,1H),1.92-1.85(m,1H) ,1.81-1.73(m,1H),1.23(s,1H),0.72-0.59(m,1H),0.48-0.30(m,1H),0.23-0.15(m,1H),0.13-0.06(m,1H).
[0514] Compound 8: Synthesized from compound 8a
[0515] Compound 8 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0516] Both are white solids. One is compound 8-P1, and the other is compound 8-P2.
[0517] 8-P1
[0518] LC-MS m / z = 514.3 [M+H] + .
[0519] 1 H NMR(400MHz,DMSO-d6)δ10.71(s,1H),8.99(s,1H),8.23-8.21(d,J=4.8Hz,1H),7.76-7 .71(m,1H),7.31-7.27(m,1H),7.21-7.17(m,2H)7.06-6.98(m,1H),6.94-6.83(m,3H), 5.66(t,J=7.6Hz,1H),5.20-5.15(m,1H),4.15-4.09(m,2H),2.68-2.59(m,1H),2.52-2 .49(m,1H),2.02-1.85(m,2H),0.72-0.72(m,1H),0.44-0.36(m,2H),0.22-0.16(m,2H).
[0520] 8-P2
[0521] LC-MS m / z = 514.3 [M+H] + .
[0522] 1 H NMR (400MHz, DMSO-d6) δ10.75(s,1H),9.25(s,1H),8.22(d,J=4.8Hz,1H),7.78–7.71(d,J=4.8Hz,1H),7.34–7.2 7(m,2H),7.20–7.16(m,1H),7.06–7.05(m,1H),7.02–6.98(m,1H)6.94–6.89(m,2H),5.60(t,J=8.0Hz,1H),5.25 –5.20(m,1H),4.01–3.99(m,1H),3.83–3.83(m,1H),2.69–2.62(m,1H),2.49–2.49(m,1H),2.03–1.96(m,1H),1. 82–1.73(m,1H),0.75–0.65(m,1H),0.37–0.30(m,1H),0.21–0.15(m,1H),0.11–0.07(m,1H),0.00–-0.05(m,1H).
[0523] Compound 5: Synthesized from compound 5a
[0524] LCMS: m / z = 531.0 [M+H] + .
[0525] 1 H NMR(400MHz,DMSO-d6)δ10.71(s,1H),8.74(s,0.6H),8.48(s,0.4H),8.03 -8.01(m,1H),7.12-7.01(m,4H),6.94-6.90(m,4H),5.62-5.60(m,1H),5.23-5.21(m,1H),4.13-3.98( m,2H),2.71-2.59(m,1H),2.46(m,1H),1.99-1.78(m,2H),0.85(m,1H),0.62-0.34(m,3H),0.19(m,1H).
[0526] Compound 7: Synthesized from compound 7a
[0527] LC-MS: m / z = 525.3 [M+H] + .
[0528] 1H NMR(400MHz,DMSO-d6)δ10.71(s,1H),9.57(s,1H),8.16(s,1H),7.65(s,1H),7.23–7.16(m,2H) ,7.02–6.98(m,2H),6.91–6.82(m,2H),5.59–5.54(m,1H),5.24–5.19(m,1H),3.97–3.94(m,1H) ,3.77–3.63(m,1H),2.67–2.61(m,1H),2.51–2.47(m,1H),2.02–1.96(m,1H),1.79–1.72(m,1H) ,0.96–0.91(m,5H),0.61–0.57(m,1H),035–0.29(m,1H),0.12–0.06(m,2H),0.03–-0.07(m,1H).
[0529] Compound 6: Synthesized from compound 6a.
[0530] Compound 6 was purified by Prep-HPLC to obtain the following two stereoisomers.
[0531] Among them, one is compound 6-P1 and the other is compound 6-P2.
[0532] 6-P1
[0533] LCMS: m / z = 499.30 [M+l] + .
[0534] NMR: 1 H NMR(400MHz,DMSO-d6)δ10.69(s,1H),9.34(s,1H),8.07(s,1H),7.61(s,1H),7.16–7.06(m,1 H),6.95(s,2H),6.84(dq,J=15.4,7.28Hz,3H),5.67(t,J=7.6Hz,1H),5.16(dd,J=8.75,6.61H z,1H),4.07(s,2H),3.80(s,3H),2.63(dd,J=13.4,8.89Hz,1H),2.49-2.45(m,1H),1.94-1.86 (m,2H),0.71–0.58(m,1H),0.46–0.29(m,2H),0.17(dq,J=8.4,4.6Hz,1H),0.08–0.04(m,1H).
[0535] 6-P2
[0536] LCMS: m / z = 499.30 [M+l] + .
[0537] NMR: 1 H NMR(400MHz,DMSO-d6)δ10.63(s,1H),9.61(s,1H),8.08(s,1H),7.62(s,1H),7.23(td,J=7.70,1.09Hz,1 H),7.15(d,J=7.2Hz,1H),7.07–6.75(m,5H),5.57-5.50(m,1H),5.23-5.15(m,1H),3.92(d,J=7.2Hz,1H), 3.80-3.70(m,4H),2.64–2.57(m,1H),2.45–2.36(m,1H),1.99–1.82(m,1H),1.71(dt,J=14.97,7.90Hz,1 H), 0.56 (dq, J=9.05, 4.88Hz, 1H), 0.29 (tt, J=9.10, 4.04Hz, 1H), 0.19–0.03 (m, 2H), -0.04–-0.11 (m, 1H).
[0538] Compound 10: synthesized from compound 10a.
[0539]
[0540] LC-MS[M+H] + =527.30.
[0541] 1HNMR (400MHz, DMSO-d6) δ10.71–10.69(d,J=7.2Hz,1H),7.95–7.94(d,J=4.8Hz,0.5H),7.74–7.73(d,J=5.2Hz,0.5H),7.42( s,0.5H),7.38(s,0.5H),7.25–7.17(m,1.5H),7.01–6.97(m,0.5H),6.91–6.80(m,2H),5.66–5.59(m,0.5H),5.54-5.50(m,0. 5H),5.22–5.18(m,1H),4.07–3.39(m,1.5H),3.89–3.87(d,J=10.4Hz,0.5H),2.85–2.72(m,1H),2.67–2.59(m,1H),2.49–2. 46(m,1H),2.00–2.54(m,1H),1.89–1.76(m,1H),0.70–0.56(m,5H),0.45–0.28(m,2H),0.20–0.15(m,1H),0.10–0.04(m,1H).
[0542] Chiral HPLC: The ratio of a pair of isomers is 55%:45%.
[0543] These are two stereoisomers of compound 10.
[0544] Biochemical test
[0545] Test 1: 3CLpro protease inhibition assay
[0546] The analyte (example compound) was serially diluted 3-fold with DMSO for 10 test sites. The solutions were added to 384 microplates using an ECHO workstation, with replicates for each test site. 25 μL of 3CLpro protease solution was added to each well of the microplate containing the analyte. The solutions were mixed and pre-incubated at room temperature for 30 min. After incubation, 5 μL of substrate (Dabcyl-KTSAVLQ∥SGFRKM-E(Edans)) was added. The final concentrations of protease 3CLpro and substrate were 25 nM and 25 μM, respectively. For the 100% inhibition (HPE, hundred percent effect) control sample, 1 μM of compound GC376 was added. For the 0% inhibition (ZPE, zero percent effect) control sample, no compound was added. The final concentration of DMSO solution was 1%. Each test point was normalized using a background control to eliminate background fluorescence interference. After incubation at 30°C for 60 minutes, the fluorescence signal (RFU) was detected using an M2e (SpectraMax) microplate reader at Ex / Em = 340nm / 490nm. The inhibition activity was calculated using the following formula: Inhibition % = [(sample - average ZPE) / (average HPE - average ZPE)] * 100%.
[0547] 3CLpro protease solution: 20 mM Tris-HCl (pH 7.3), 100 mM NaCl, 1 mM EDTA, 5 mM TCEP and 0.1% BSA.
[0548] HEP: 100% inhibition control sample. Contains substrate + 3CLpro protease solution + 1μM GC376.
[0549] ZPE: 0% inhibition control sample. Contains substrate + 3CLpro protease solution, no analyte.
[0550] Sample: Compound activity test sample. Contains substrate + 3CLpro protease solution + analyte.
[0551] Background control: Contains analyte and substrate, but does not contain protease.
[0552] Plot the inhibition curve and calculate the half-maximal inhibitory concentration (IC50). 50 The results are shown in Table 1.
[0553] The compounds of this invention have 3CLpro protease inhibitory activity comparable to nematvir.
[0554] Test 2: In vitro SARS-CoV-2 replicon antiviral assay
[0555] The analyte was serially diluted 3-fold with DMSO solution, for a total of 8 test sites. 0.3 μL of the analyte solution was added to 384 microplates, with replicates for each test site. RNA replicons were obtained through in vitro transcription (the transcribed RNA was purified using the RNeasyMinElute Cleanup Kit (QIAGEN74204), OD260 / 280≈2, RNA Conc≥1000 ng / μL). Huh7 cells were transfected with purified SARS-CoV-2 replicon RNA (the constructed Replicon was from GenBank: NC045512, with a T7 promoter added to the 5' end, the ORFs of the S and E genes deleted, and the EGFP and bsd genes replaced, respectively. The 3' end retained PolyA, and an HDV ribozyme sequence and T7 Terminator were added, ligated into the BAC vector (GENWIZ), and the linearized in vitro transcribed and purified RNA was electroporated into cells). The cells were seeded at 4000 cells / well. The cells were cultured in 384-well microplates containing serially diluted compounds and then incubated at 37°C and 5% CO2 for 1 day. The final volume of the cell culture was 60 μL per well, and the final concentration of DMSO in the test plate was 0.5%.
[0556] Fluorescence intensity was measured using Acumen Cellista (TTP LabTech), and the antiviral activity of the compound was calculated based on the inhibition of GFP expression. Cell viability was measured using CellTiter Glo according to the instructions for use.
[0557] The antiviral activity and cell viability of the compounds are expressed as % inhibition and % viability, respectively, and are calculated using the following formula:
[0558] Inhibition rate (%) = (CPD – mean ZPE) / (mean HPE – mean ZPE) * 100
[0559] Cell viability (%) = (CPD – mean HPE) / (mean ZPE – mean HPE) * 100
[0560] CPD: Measured value of a sample containing the analyte.
[0561] ZPE: Average value of virus control
[0562] HPE: Average value of the blank control (containing only culture medium).
[0563] A nonlinear four-parameter model was used to fit the inhibition rate-response relationship of the natural logarithm transformation, and EC was calculated. 50 and CC 50 Values. Results are shown in Table 1. The software used is GraphPad Prism.
[0564] The compounds of this invention have antiviral activity and cell viability comparable to nematvir.
[0565] Table 1
[0566] Compound numbering <![CDATA[IC 50 (nM)]]> <![CDATA[EC 50 (nM)]]> <![CDATA[CC 50 (nM)]]> Nirmatrelvir A A >1000 1 A A >1000 2 A A >1000 3 B A >1000 4 A A >1000 5 A A >1000 6 A A >1000 8 A A >1000 10 A A >1000 11 A A >1000 12 A A >1000 13 A A >1000 14 A A >1000 15 A A >1000 16 A A >1000 17 A A >1000 18 A A >1000 19 A A >1000 20 A B >1000 22 A A >1000 24 A A >1000 25 A A >1000 26 A A >1000 27 B B >1000
[0567] Note: A≤100, B 100-1000, C>1000.
[0568] Test 3: Stability of human liver microsomes
[0569] The analyte was dissolved in DMSO to prepare a 10 mM stock solution, which was then diluted to 100 μM with ACN:H2O at a ratio of 1:1 (v / v) to obtain the working solution. The working solution was diluted to 1 μM in potassium phosphate buffer (100 mM, pH 7.4) containing MgCl2 (3 mM), NADPH (1 mM), and HLM (1 mg / mL, human liver microsomes), to a final volume of 200 μL, and incubated at 37 °C in a shaker. Incubation was performed in the presence and absence of the selective CYP3A inhibitor ketoconazole (1 μM). Incubation was terminated at selected time points (0, 5, 15, 30, 45, 60, and 80 min) by adding 200 μL of acetonitrile (containing 300 ng / mL tolbutamide) to 100 μL of sample, followed by shaking for 5 min, centrifugation at 3700 rpm for 15 min. The supernatant was transferred to a 96-well plate, diluted with mobile phase A (0.1% formic acid aqueous solution), and analyzed using liquid chromatography-mass spectrometry (LC-MS / MS). Half-life t 1 / 2 Calculation formula t 1 / 2 = -0.693 / k, data are shown in Table 2, where k is the slope of the peak area ratio-time linear fit after natural logarithm transformation.
[0570] Compounds 1-25 of the present invention have better human liver microsomal stability (i.e., oxidase stability) than nematidine, and compounds 26 and 27 have human liver microsomal stability (i.e., oxidase stability) comparable to nematidine.
[0571] Table 2
[0572] Compound numbering Human liver microsomal half-life t1 / 2 (min) Nirmatrelvir C 5 B 12 B 13 B 14 A 16 B 17 B 18 A 20 A 22 B 26 C
[0573] Note: t1 / 2 (min): A>100, B 30~100, C<30.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt thereof, characterized in that, The compound shown in Formula I is selected from any of the following compounds: , , , , , , , and .
2. The compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof, characterized in that, The compound shown in Formula I is selected from any of the following compounds: , , , , , , , , , , , , , , , , and .
3. A pharmaceutical composition, characterized in that, It comprises a compound of formula I as described in claim 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. An application of substance A, characterized in that, Substance A is the pharmaceutical composition as described in claim 3; The application is in the preparation of 3CLpro protease inhibitors or in the preparation of medicaments for the treatment and / or prevention of diseases caused by coronavirus infection; The coronavirus in question is SARS-CoV-2.
Citation Information
Patent Citations
Nitrile-containing antiviral compounds
WO2021250648A1
Novel spiropyrrolidine derived antiviral agents
WO2023009187A1
